Michael J. Fox Foundation awards $299,000 to Promentis Pharmaceuticals, Inc. to develop Parkinson’s disease drugs

Promentis Pharmaceuticals, Inc. announced today that it has been awarded funding by The Michael J. Fox Foundation (MJFF) to conduct pre-clinical research targeting compounds that show promise as neuroprotective agents for patients suffering from Parkinson’s disease.

August 24, 2012

Promentis Pharmaceuticals, Inc. announced today that it has been awarded funding by The Michael J. Fox Foundation (MJFF) to conduct pre-clinical research targeting compounds that show promise as neuroprotective agents for patients suffering from Parkinson’s disease.

About Promentis Pharmaceuticals, Inc:

Promentis Pharmaceuticals, Inc. was founded in 2007 and is a private, emerging pharmaceutical company focused on developing unique compounds aimed at modifying brain chemistry for the treatment of schizophrenia and other central nervous system (CNS) disorders.  Support for Promentis’ drug discovery and development programs, in part, has been provided by recent grants from the National Institute of Mental Health (NIMH) and the Michael J. Fox Foundation.  Additional information can be found at www.promentispharma.com.

Media Inquiries:
Andrew Mielach
Tiberend Strategic Advisors, Inc.
(212) 375-2694
amielach@tiberend.com

SOURCE Promentis Pharmaceuticals, Inc.

RELATED LINKS

http://www.promentispharma.com